Akkermansia muciniphila MucT
Commercial- Indications
- Gut barrier dysfunction
Company intelligence / Profile preview
The Akkermansia Company
Belgiumtheakkermansiacompany.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The Akkermansia Company has developed the first EFSA-approved next-generation beneficial bacterium product based on Akkermansia muciniphila, with demonstrated benefits in weight management and metabolic health. Human studies show improved insulin sensitivity and reduced inflammation markers. Their lead product uses a patented pasteurization process to enhance efficacy and stability. Commercial launch began after EU approval in late 2021–2022.
- Therapeutic areas
- GastroenterologyEndocrinologyCardiovascular
- Modalities
- Postbiotic (pasteurized bacteria)Probiotic (live bacteria in research context)Nutritional supplement/food ingredientMonoclonal antibodies (patent application)
- Industry
- Non-Drug Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Metagenics Europe – exclusive distribution partner for BeNeLux region and ItalySacco System involved in production/distribution processes.
Beyond the preview
Go deeper on The Akkermansia Company.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on The Akkermansia Company.